Subscribe to Updates in Healthcare

RSS By Email

RSS By RSS

Add to Google Reader or Homepage

Subscribe in Bloglines


The Expertise Imperative and Compliance Technology
Access to a diverse array of specialized expert inputs drives superior decisions in every organizational context: within corporations, by investors and consultancies, and within nonprofits. When decision makers are confident of their decision inputs, they can respond more quickly and creatively to challenges and opportunities.Learn more about GLG's Compliance Framework


This page may include content provided by Council Members, your access to which is subject to the Terms of Use.
Find Out More

Study Group: Allergists (US)(?)

Council Members in this Study Group: 404

This study group may include physicians, care providers, and researchers specializing in internal medicine, cardiology, oncology, dermatology, emergency medicine, family medicine, neurology, obstetrics-gynecology, psychiatry, radiology, nursing, optometry, genetics, and mental health. It may also include experts knowledgeable on diagnostic labs, disease management, medical devices, long term care, surgery centers, health management, pharma, and biotechnology, among others.

Request a survey with this Study Group







Leading Experts in this Study Group

Michael Wechsler, MD
Associate Physician in Pulmonary and Critical Care
BRIGHAM AND WOMEN'S HOSPITAL

Michael Wechsler, MD, is an Associate Physician in the Pulmonary and Critical Care Division of Brigham and Women's Hospital in Boston and is on the faculty at Harvard Medical School. He is a member of the Steering Committee of the NIH's Asthma Clinical Research Network and is active in both basic and...

Michael Blaiss, MD, Partner, Allergy & Asthma CareMichael Blaiss, MD
Partner
Allergy & Asthma Care

Michael S. Blaiss, MD, is a Clinical Professor of Pediatrics and Medicine at University of Tennessee Health Sciences Center and in private practice at Allergy & Asthma Care in Memphis. Dr. Blaiss’s clinical focus is on allergies and has expertise in outcomes research in allergic disorders, especially...

David Engler, MD, Physician, The Allergy ClinicDavid Engler, MD
Physician
The Allergy Clinic

David Engler, MD, a graduate of Baylor College of Medicine, has worked at The Allergy Clinic since 1991. He has served two terms on the Board of Regents of the American College of Allergy, Asthma & Immunology, and has represented that organization at the A.M.A. Dr. Engler has a busy sub-specialty...

Mitchell Boxer, MD
Assistant Clinical Professor
Albert Einstein College of Medicine

Mitchell Boxer, MD, is Director of the Adult Allergy Section at Long Island Jewish Medical Center and Assistant Clinical Professor at Albert Einstein Medical College. Dr. Boxer completed his fellowship at Northwestern University Medical College and has expertise in a wide range of allergic and immunologic...

Steven Weinstein, MD
Director
Allergy and Asthma Specialists Medical Group & Research Center

Steven Weinstein, MD, is the Director of Allergy and Asthma Specialists Medical Group and Research Center, California. He also holds an academic appointment as Clinical Professor of Allergy and Immunology in the Department of Pediatrics at the University of California, Irvine, School of Medicine. Dr....

GLG NewsSMAnalyses by this Study Group's Leading Experts(?)

Opinions and analyses expressed in GLG News are solely those of the author. See the Terms of Use for details.
What do you expect in hard economic times? | 07-18-2008
Analysis of: Patients Curb Prescription Spending | online.wsj.com
Author: GLG Expert Contributor

With the economy in recession, whether we are willing to say it or not; with increased cost of food, gas, etc.; what do you expect. Patients are askiing and getting generics. This is on top of most PBM and managed care companies whose P4P includes generic use and stress this to the patient.

Too much of a good thing | 07-18-2008
Analysis of: Drugs to Build Bones May Weaken Them | www.nytimes.com
Author: GLG Expert Contributor

This report suggest that there is a point in therapy where we start seiing negative effects from the use of bisphosphanates. There needs to be guidelines on length of therapy. Too long may lead to adverse effects.

Desperate times- desperate measures | 07-11-2008
Author: GLG Expert Contributor

This recommedation is just a reflection of how out of hand the crisis of obesity and metabolic syndrome/diabetes is in our youth. We all need to wake up and do something.

yes! | 07-03-2008
Analysis of: One drug, many uses. Good idea? | www.indystar.com
Author: GLG Expert Contributor

When drug studies are done some unexpected findings emerge. If these results can show promise and expand drug use they should be persued as the cost will likely be less than developing a whole new drug.

Safety first? | 07-03-2008
Author: GLG Expert Contributor

It is likely that with all the bad press the FDA will require many more safety studies prior to allowing a drug on the market. Many nmay not make it because it will be too prohibitive to do. There is NO magic safe pill however.

View All GLG News by members of this Study Group

Most Common Company Types:

  • Office Based Private Practice or Clinic
  • Academic Medical Center/Hospital or Clinic
  • Non-Academic Community Hospital or Clinic
  • Academic Institution*

Most Common Job Types:

  • Physician - Attending Physician
  • Owner
  • Physician - Director
  • President
  • Director
  • Physician - Division Head
  • Partner
  • Professor

GLG's 750+ Clients Include:

40 of the leading 50
global mutual funds
15 of the leading 20
global banks
8 of the leading 10
private equity firms
90%+ client subscription renewal rate

Analytics